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Abstract
Background: To better characterize the value of cerebrospinal fluid (CSF) proteins as diagnostic markers in a
clinical population of subacute encephalopathy patients with relatively low prevalence of sporadic Creutzfeldt-
Jakob disease (sCJD), we studied the diagnostic accuracies of several such markers (14-3-3, tau and S100B) in 1000
prospectively and sequentially recruited Canadian patients with clinically suspected sCJD.
Methods: The study included 127 patients with autopsy-confirmed sCJD (prevalence = 12.7%) and 873 with
probable non-CJD diagnoses. Standard statistical measures of diagnostic accuracy were employed, including
sensitivity (Se), specificity (Sp), predictive values (PVs), likelihood ratios (LRs), and Receiver Operating Characteristic
(ROC) analysis.
Results: At optimal cutoff thresholds (empirically selected for 14-3-3, assayed by immunoblot; 976 pg/mL for tau
and 2.5 ng/mL for S100B, both assayed by ELISA), Se and Sp respectively were 0.88 (95% CI, 0.81-0.93) and 0.72
(0.69-0.75) for 14-3-3; 0.91 (0.84-0.95) and 0.88 (0.85-0.90) for tau; and 0.87 (0.80-0.92) and 0.87 (0.84-0.89) for S100B.
The observed differences in Sp between 14-3-3 and either of the other 2 markers were statistically significant.
Positive LRs were 3.1 (2.8-3.6) for 14-3-3; 7.4 (6.9-7.8) for tau; and 6.6 (6.1-7.1) for S100B. Negative LRs were 0.16
(0.10-0.26) for 14-3-3; 0.10 (0.06-0.20) for tau; and 0.15 (0.09-0.20) for S100B. Estimates of areas under ROC curves
were 0.947 (0.931-0.961) for tau and 0.908 (0.888-0.926) for S100B. Use of interval LRs (iLRs) significantly enhanced
accuracy for patient subsets [e.g., 41/120 (34.2%) of tested sCJD patients displayed tau levels > 10,000 pg/mL, with
an iLR of 56.4 (22.8-140.0)], as did combining tau and S100B [e.g., for tau > 976 pg/mL and S100B > 2.5 ng/mL,
positive LR = 18.0 (12.9-25.0) and negative LR = 0.02 (0.01-0.09)].
Conclusions: CSF 14-3-3, tau and S100B proteins are useful diagnostic markers of sCJD even in a low-prevalence
clinical population. CSF tau showed better overall diagnostic accuracy than 14-3-3 or S100B. Reporting of
quantitative assay results and combining tau with S100B could enhance case definitions used in diagnosis and
surveillance of sCJD.
Background
Prion diseases are rare neurodegenerative disorders that
arise sporadically, genetically, or by infectious transmis-
sion. They are marked by spongiform change, neuronal
loss, and deposition of a misfolded host-encoded glyco-
protein (PrP
Sc)i nb r a i nt i s s u et h a ti sg e n e r a l l y
considered to constitute the transmissible agent [1].
Despite their rarity, the economic and public-health
impacts of human prion diseases [2] maintain a need for
detailed surveillance and prompt diagnosis, usually with
support from expert reference units [3]. Sporadic
Creutzfeldt-Jakob disease (sCJD) accounts for 80-90% of
annual human prion disease mortality (~1-2 per million)
[4]. With its subtype heterogeneity [5] and diverse pre-
senting symptoms [6] that may accompany other condi-
tions [7], differentiation of sCJD from other subacute
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on a first encounter [8]. Surveillance-oriented sCJD case
definitions are available [3], with recent updates includ-
ing MRI criteria [9]. However, definitive, non-invasive
diagnostic laboratory tests for sCJD that could be
applied to the living patient remain elusive, largely
because pathologic PrP
Sc is found only in trace amounts
in body fluids. Recent technical developments promise
to eventually allow the reliable ultrasensitive detection
of PrP
Sc in such samples [10,11]; however, for the
moment definitive diagnosis of sCJD remains highly
dependent on direct examination of brain tissue [12].
Certain brain proteins found in cerebrospinal fluid
(CSF) - in particular 14-3-3 proteins, microtubule-asso-
ciated protein tau, neuron-specific enolase, and S100B -
have demonstrated their utility as sCJD markers [13-15]
but produce some discordant results that have raised
questions regarding their fitness for diagnostic purposes
[16,17]. In one large multi-center study for example
[13], diagnostic sensitivity and specificity for sCJD were
estimated at 0.85 and 0.84 respectively for CSF 14-3-3
protein; 0.86 and 0.88 for microtubule-associated pro-
tein tau; 0.73 and 0.95 for neuron-specific enolase; and
0.82 and 0.76 for S100B. Some single-centre studies
have reported better performance, although still with
false positives and false negatives [14,15].
Such inaccuracies can have significant negative impact
on patients and institutions, prompting advice that 14-
3-3 in particular should only be used within an “appro-
priate clinical context” [18], or perhaps should not be
used [17]. Nevertheless, surveillance case definitions of
probable sCJD still include a positive 14-3-3 assay [3],
and use of 14-3-3 reference services is positively corre-
lated with observed sCJD mortality rates [19]. The use
of CSF markers in sCJD diagnosis per se is also likely to
continue - the 14-3-3 assay in particular remains the
most frequently requested laboratory test for human
prion diseases. Precise quantitative estimates of these
markers’ performance characteristics are therefore
needed, for timely revision of diagnostic probabilities
[20,21]. Such a framework should also be applicable to
screening of a broad range of patients for whom a suspi-
cion of sCJD exists, and not only to strengthen confir-
mation of the disease (or its absence) in a select group
for whom pre-test diagnostic probabilities are already
highly refined [22].
The Public Health Agency of Canada’sC r e u t z f e l d t -
Jakob Disease Surveillance System (CJDSS) has con-
ducted prospective, autopsy-based surveillance of human
prion diseases in Canada since April 1 1998, with the
objective of identifying and characterizing all cases of
human prion disease in Canada. As final diagnostic clas-
sifications and most laboratory tests (including all CSF
testing) are performed centrally using standard methods
a n dc r i t e r i a[ 3 ] ,w ew e r ea f f o r d e da no p p o r t u n i t yt o
simultaneously validate the respective abilities of several
known CSF protein markers (14-3-3, tau and S100B) to
differentiate sCJD from a broad range of other condi-
tions prompting suspicion of sCJD. Here we report
results of a prospective study of diagnostic accuracies of
CSF 14-3-3, tau and S100B proteins in 1000 sequentially
recruited Canadian patients, including 127 with neuro-
pathologically confirmed sCJD. Our results indicate that
these markers can have substantial diagnostic power
even when used in a heterogeneous patient population
with low average pre-test probability of sCJD. A preli-
minary abstract of these findings has been previously
published [23].
Methods
Participants
CJD surveillance takes place in Canada through direct
case-by-case consultation between the CJDSS and colla-
borating health professionals, with laboratory reference
services provided by the CJDSS for neuropathology,
molecular genetics, and CSF 14-3-3 protein testing. Fol-
lowing initial identification of a suspected case, a stan-
dard intake questionnaire is completed to collect
information on the patient’s symptoms, signs, history,
results of previous investigations, and current status.
The case is then followed throughout the course of the
patient’s illness, as long as prion disease remains sus-
pected and the prospect of patient enrolment for full
case investigation remains open. Case files are main-
tained centrally and remain open until all available
information has been collected. Infectious and genetic
risk factor information is investigated by a standardized
questionnaire and medical chart review; cases are then
classified using internationally standardized criteria [3].
Non-prion disease (non-CJD) diagnoses are routinely
ascertained wherever possible, either directly via CJDSS
laboratory investigations, or by elicitation from the col-
laborating health professional at the time of file closure.
Laboratory procedures
Formalin-fixed brain tissues obtained by autopsy or
biopsy were processed for neuropathological examina-
tion using standard techniques. Slides were stained with
haematoxylin and eosin, Periodic Acid-Schiff’s reagent,
and anti-prion protein immunohistochemistry with
mouse monoclonal antibody 12F10 (189710, Cayman
Chemical, Ann Arbor, MI, USA) at a 1:2000 working
dilution. Additional stains were used when an alternative
diagnosis was suspected based on histological findings.
Slides were evaluated by two expert reviewers [3].
Codons 3-254 and 101 nucleotides of the 3’ untrans-
lated region of exon 2 in the PRNP gene were amplified
by polymerase chain reaction with primers D (5’
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TGTTGCACTAAGTCC 3’), and sequenced on both
strands with multiple oligodeoxynucleotide primers
using dideoxynucleotide chain-termination chemistry.
CSF specimens were shipped to the CJDSS laboratory
on dry ice, thawed upon receipt, and either analyzed on
the same day or immediately re-frozen and stored at
-80°C pending analysis. 14-3-3 protein was assayed
using a slightly modified version of a standard chemilu-
minescence-based immunoblotting protocol [18] on a
20-μL aliquot of CSF. Immunodetection employed a
mouse monoclonal primary antibody against the N-ter-
minus of human 14-3-3 b (SC-1657, Santa Cruz Bio-
t e c h n o l o g y ,S a n t aC r u z ,C A ,U S A ) .E a c hg e li n c l u d e d
internal standards, consisting of a standard dilution ser-
ies of recombinant human 14-3-3 g protein (National
Institute for Biological Standards and Control, Potters
Bar, Hertsfordshire, UK; or prepared in-house - note
that SC-1657 cross-reacts with human 14-3-3 g). The
positive/negative scoring threshold for 14-3-3 was initi-
ally selected to consistently produce a faint band on the
X-ray film, and corresponded to the immunoreactivity
of approximately 1.5 ng of recombinant 14-3-3 g protein
per lane. Films were scored by a single observer (MBC)
throughout, with concurrence from a second observer
(DLG).
After reporting of the 14-3-3 result, where sufficient
sample remained tau and S100B protein assays were
performed on the same CSF specimens, ensuring a fully
prospective, sequential, “one-gate” design blinded to the
final diagnostic result. Assays for CSF tau and S100B
proteins were performed using Innotest
® hTAU Ag
(Innogenetics, Ghent, Belgium) and Sangtec
® 100 (Dia-
sorin, Saluggia, Italy) ELISA kits, following instructions
provided by the manufacturer. Interim storage of sam-
ples between analytic procedures was at -80°C, and
freeze-thaw cycles were kept to a minimum after receipt
from submitting laboratories. Calibration standards for
ELISA assays were reconstituted fresh for each run. Lot-
specific internal controls with expected ranges of values
are provided by the manufacturer of the Sangtec
® 100
kit, and were run with every assay; such control materi-
als are not yet available for the Innotest
® hTAU Ag kit.
In all cases 2 replicate assays were carried out on each
clinical sample, control or calibration standard, and the
arithmetic mean of the 2 readings was taken as the sam-
ple result. The criterion for acceptance of an assay result
(which was not violated in the course of this study) was
that the coefficient of variation of the 2 replicates within
a run was no greater than 20%. Sample readings outside
the ranges of kit standards were resolved if possible by
sample dilution using diluents provided with the kit.
Where this was not possible, for purposes of data
analysis assay results were equated with concentrations
of the uppermost or lowermost standards.
Composition and statistical analysis of dataset
CSF marker data were collected prospectively from the
ongoing series of samples submitted to the CJDSS for
14-3-3 protein testing. Data were analyzed from the first
1000 contiguous CSF samples submitted after April 1,
2004 for which 14-3-3 tests were completed, final
patient diagnoses were available, and none of the follow-
ing exclusion criteria applied: (i) the sample was techni-
cally inadequate for 14-3-3 testing (insufficient volume,
xanthochromia or visible blood); (ii) more than one
technically adequate sample was submitted for the same
patient (results from one of the replicate samples were
then randomly included for analysis); (iii) the CJDSS
was unable to confirm that prion disease was suspected
at the time of CSF sample submission (clinical or cleri-
cal errors); (iv) the 14-3-3 assay result was indeterminate
due to molecular-weight anomalies of reactive bands on
the immunoblot; (v) final diagnostic classification was
genetic prion disease; (vi) final diagnostic classification
was probable sCJD (as a positive 14-3-3 result was used
as a criterion to classify such cases, they could not be
included in the validation study for this marker); or (vii)
the case remained open at study closure (July 31 2010).
For 946 of these 1000 samples sufficient volume was
available to assay total tau protein, and for 924 to assay
S100B protein.
Statistical and graphical procedures were executed
with MedCalc
® for Windows v. 11.2.1.0 (MedCalc Soft-
ware, Mariakerke, Belgium), Confidence Interval Analy-
sis [24], Post_Test_Probabilities [25], and online clinical
research calculators available on the Vassar Stats website
[26]. Relevant definitions and theory are presented by
Sackett et al.[ 2 0 ]a n dG r i m e s[ 2 1 ] .D i a g n o s t i cc u t o f f
thresholds are denoted in the text by subscripts; e.g.,
T976 for 976 pg/mL of tau, and S2.5 for 2.5 ng/mL of
S100B. To determine whether our study sample was of
adequate size to perform valid logistic regression ana-
lyses, an estimate of the minimum number of cases
required is given by N = 10 k/p, where k is the number
of independent variables, and p is the smaller of the
proportions of positive and negative cases in the popula-
tion sample [27]. We performed two logistic regression
analyses with k = 2 or 3, and p = 0.127 (for sCJD) in
both cases; thus, N = 157.5 or 236.2. Since the number
of cases in each of these analyses was 913, this criterion
was satisfied.
Ethics statement
Enrolment in the CJDSS takes place with written
informed consent, under a protocol approved by the
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Research Ethics Board (Certificate REB-2009-0036).
Results
Study population
Between April 1 2004 and July 31 2010, a total of 1,183
CSF samples were received by the CJDSS reference
laboratory for 14-3-3 testing. Of the 1000 of these
selected for inclusion in the study (see Methods), in 127
cases sCJD was subsequently confirmed by positive neu-
ropathology without evidence of an infectious or genetic
cause. Of the 873 non-CJD cases, 543 (62.2%) were
assigned a specific final diagnosis other than prion dis-
ease (see Additional file: 1, Table S1), and 330 (37.8%)
had an unknown diagnosis but no further suspicion of
prion disease, thereby qualifying them as “probable non-
CJD”. A total of 29 patients with a diagnosis of probable
sCJD were excluded from the statistical analysis (see
M e t h o d s ) .N of i n a ld i a g n o s e so fp o s s i b l es C J Dw e r e
assigned. Minimum prevalence of sCJD in the study
population was thus estimated to be 127/1000, or 0.127
[95% Confidence Interval (CI): 0.107-0.150]. A flowchart
summarizing numbers of samples, tests and diagnoses is
shown in Figure 1.
Median age of sCJD cases at notification was 66 (95%
CI: 63-69) years, and that of the 866 non-CJD cases for
whom data were available was 63 (95% CI: 62-64) years.
Numbers of PRNP codon 129 genotypes among the 72
sCJD patients tested were 44 MM (61.1%), 16 MV
(22.2%), and 12 VV (16.7%). Of the sCJD cases, 66/127
(52.0%) were male; of non-CJD cases, 448/873 (51.3%).
Single marker performance
Receiver operating characteristic (ROC) curves were
plotted for tau and S100B in the 913 cases tested for
both markers (Figure 2). Diagnostic sensitivity (Se) and
specificity (Sp) were co-optimized by maximizing the
Youden Index (Se + Sp - 1) at cutoff thresholds of 976
pg/mL (T976) for tau and 2.5 ng/mL (S2.5)f o rS 1 0 0 B .
Estimates of area under the curve (AUC) were 0.95
(95% CI: 0.93-0.96) for tau and 0.91 (95% CI: 0.89-0.93)
for S100B, implying significant discriminatory power of
both markers in this patient population (P < 0.0001 for
AUC > 0.5, DeLong test) as well as slight but statisti-
cally significant differences between them (P = 0.03,
DeLong test).
Se, Sp, and positive and negative likelihood ratios (LR
+,L R
-) were estimated for 14-3-3, tau and S100B (Table
1), applying either our estimated optimal thresholds or,
for the ELISA assays, consensus thresholds (T1300,S 4.2)
widely applied by other CJD reference laboratories using
the same reagent kits [13]. With optimal thresholds, five
of the six Se and Sp estimates were in the range 0.84-
0.91, with the exception being 14-3-3 Sp at 0.72 (95%
CI: 0.69-0.75). Newcombe’s method for differences of
proportions [24] was used to test all 6 pairwise differ-
ences of Se and Sp between markers. Based on non-
inclusion of zero in 95% confidence intervals for these
differences the only significant differences occurred
between Sp of 14-3-3 and that of either of the other two
markers; this comparison was significant regardless of
whether all non-CJD cases were included, or only those
with specific non-CJD diagnoses. As expected, use of
the higher consensus thresholds decreased Se and
increased Sp for both tau and S100B.
LR
+ estimates at optimal thresholds were lowest for
14-3-3 at 3.1 (95% CI: 2.8-3.6), versus those for tau and
S100B at 7.4 (95% CI: 6.9-7.8) and 6.6 (95% CI: 6.1-7.1),
respectively. LR
- estimates were lowest for tau at 0.10
(95% CI: 0.06-0.20), versus those for 14-3-3 and S100B
at 0.16 (95% CI: 0.10-0.26) and 0.15 (95% CI: 0.09-0.20),
respectively. Again, the estimates for tau and S100B all
shifted when the consensus thresholds were applied
(Table 1). We also calculated interval likelihood ratios
(iLRs) for illustrative sub-ranges of tau and S100B assay
results (Table 2). Significant variation was observed
across intervals in their power to support or exclude a
diagnosis of sCJD. With tau for example, above T10,000
the iLR rose significantly to 56.4 (95% CI: 22.8-140.0),
and below T500 fell to 0.06 (95% CI: 0.03-0.14). With
S100B, above S4.0 the iLR was 14.6 (95% CI: 10.0-21.4),
and below S2.0 was 0.09 (95% CI: 0.05-0.18).
Joint marker performance
Tau and S100B values were plotted jointly for 118 sCJD
and 795 non-CJD cases tested for both markers (Figure
3). The two markers were significantly correlated
[Spearman’s r, 0.422 (95% CI: 0.261-0.560, p < 0.0001)
for sCJD; and 0.346 (95% CI: 0.283-0.406, p < 0.0001)
for non-CJD]. However, sCJD cases showed a visible
tendency toward simultaneous elevation of both mar-
kers, while a large majority of non-CJD data points fell
closer to one or both axes.
To quantitatively assess the potential added diagnostic
power of combining tau and S100B results in this study
population only, we performed a multiple logistic regres-
sion analysis with tau and S100B as independent vari-
ables and logit of diagnosis (sCJD) as the dependent
variable. The overall regression model, logit(p) = -3.4907
+ 0.0005279 × [tau] + 0.09543 × [S100B] was statisti-
cally significant (P < 0.0001, Chi-square likelihood ratio
test, 2 df). P values were < 0.0001 and 0.0052 for the
regression coefficients of [tau] and [S100B] respectively,
supporting the conclusion that each marker had a signif-
icant positive effect on the probability of a diagnosis of
sCJD. ROC curves for tau, S100B and their joint regres-
sion-derived bivariate risk scores were then compared.
As mentioned earlier, AUC estimates for the subset of
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0.95 (95% CI: 0.93-0.96) for tau and 0.91 (95% CI: 0.89-
0.93) for S100B; AUC for the bivariate risk score was
0.96 (95% CI: 0.94-0.97). Pairwise comparisons of AUC
between both bivariate risk score versus tau, and bivari-
ate risk score versus S100B, showed significant differ-
ences (P = 0.0241 and 0.0051, respectively), supporting
the interpretation that combining these two markers
increased overall discriminatory power over that of
either marker alone in our study population.
To further characterize the joint diagnostic perfor-
mance of tau and S100B using a different approach, we
constructed 2 × 2 contingency tables using 6 illustrative
discrete bivariate cutoff thresholds defined by combina-
tions of (S2.5 OR S5.0)A N D( T 976 OR T3000 OR T5000).
Resulting joint LR
+ estimates (Table 3) ranged from
Eligible  CSF
  samples  received
n  =  1183
•  14-3-3  immunoblot
Neuropathology
n  =  170
No
neuropathology
n  =  864
Definite
prion  disease
n  =  132
Genetic  prion
disease
n  =  5
Probable
sCJD
n  =  29  Non-prion  disease
n  =  38
Alternate  diagnosis
n  =  33
No
alternate  diagnosis
n  =  5
Non-prion  disease
n  =  835
Alternate  diagnosis
n  =  510
No
alternate  diagnosis
n  =  325
Case  follow-up
and  tracking
n  =  1068
CJD  not 
suspected
n  =  13
Case  file 
still  open
n  =  21
Technically  inadequate
n  =  68 Clerical  error
n  =  6 Duplicate  submission
n  =  40
Indeterminate
14-3-3  result
n  =  1
•  Tau  ELISA
•  S100B  ELISA
n  =  1069
No
genetic  analysis
n  =  55 Genetic  analysis
n  =  77
Definite  sCJD
n  =  72
Figure 1 Sample intake, laboratory testing, case follow-up and final case classification. Numbers of CSF samples received and processed,
and numbers of suspected CJD cases followed up, examined by neuropathology and classified, used to constitute the clinical population on
which the study was based. Details of inclusion and classification criteria are explained further in the text.
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20.7-158.5) for S5.0 +T 5000. Thus, in our study popula-
tion a combination of S100B > 5.0 ng/mL and tau >
5000 pg/mL affords as much power to rule in sCJD as a
tau result of > 10,000 pg/mL, with its individual iLR
estimate of 56.4 (95% CI: 22.8-140.0) (cf. Table 2). Con-
versely, for a joint assay result below S2.5 +T 1000 the
LR
- estimate was 0.02 (95% CI: 0.01-0.08), indicating
enhanced discrimination against a diagnosis of sCJD
when both assay results fall below their individually
optimal thresholds (cf. Table 1).
To assess the potential added value of 14-3-3, we also
compared AUC estimates for trivariate risk scores for
diagnosis of sCJD derived by logistic regression using all
three markers as independent variables, to AUC esti-
mates for the bivariate risk estimates derived as above
for Tau and S100B. The estimate of AUC for the
trivariate risk score was 0.94 (95% CI: 0.93-0.96), signifi-
cantly smaller than that for the bivariate risk score (P =
0.0297, DeLong test), indicating that if anything, the
inclusion of 14-3-3 reduces discriminatory power for a
diagnosis of sCJD. Lastly, we calculated LR
+ and LR
-
values jointly for all three markers using the approach
based on discrete illustrative cutoff thresholds, and com-
p a r e dt h e mw i t ht h o s eo b t a i n e df o rt a ua n dS 1 0 0 B .
Based on the very similar LR estimates their broadly
overlapping confidence intervals, again we did not
observe any evidence for diagnostic value of 14-3-3
beyond that available from tau and S100B (Table 3).
Post-test probabilities and examples of application
To explore the diagnostic implications of marker perfor-
mance characteristics, we used a Bayesian modeling
approach [25] to provide point estimates and 95% cred-
ible intervals for post-test probability (PTP) of a diagno-
sis of sCJD given either a positive (PTP
+) or negative
(PTP
-)a s s a yr e s u l t( n o t et h a tP T P
+ is logically equiva-
lent to positive predictive value, PV
+,a n dP T P
- is the
complement of negative predictive value, 1 - PV
-). With
optimal cutoff thresholds and a pre-test probability
equivalent to the overall prevalence of sCJD in the study
population, 0.127 (95% CI: 0.107-0.150), diagnostic
probabilities for sCJD were clearly less strongly modified
by a positive 14-3-3 result (PTP
+ = 0.31, 95% credible
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Figure 2 Receiver Operating Characteristic (ROC) curves for tau
and S100B, plotted for 913 sCJD and non-CJD patients on
whom both markers were assayed. Solid line indicates ROC curve
for tau; dashed line indicates ROC curve for S100B; dotted line
indicates diagonal representing a hypothetical test with no
diagnostic discrimination.
Table 1 Performance characteristics for 14-3-3, tau and S100B.
Marker Threshold Se
a 95%CI Sp
a 95% CI LR
+a 95% CI LR
-a 95% CI
14-3-3 - 0.88 0.81-0.93 0.72 0.69-0.75 3.1 2.8-3.6 0.16 0.10-0.26
Tau 976
b 0.91 0.84-0.95 0.88 0.85-0.90 7.4 6.9-7.8 0.10 0.06-0.20
1300
c 0.84 0.76-0.90 0.92 0.90-0.94 10.9 8.5-13.9 0.17 0.11-0.26
S100B 2.5
b 0.87 0.80-0.92 0.87 0.84-0.91 6.6 6.1-7.1 0.15 0.09-0.20
4.2
c 0.52 0.42-0.61 0.97 0.95-0.98 15.3 10.2-23.1 0.50 0.42-0.60
a Se - sensitivity, Sp - specificity, LR
+ - positive likelihood ratio, LR
- - negative likelihood ratio.
b Optimal scoring thresholds for tau and S100B, estimated in this study. Values are in pg/mL for tau, and in ng/mL for S100B.
c Consensus scoring thresholds for tau and S100B, based on published literature.
Table 2 Interval likelihood ratios for tau and S100B
Marker Interval
a N (sCJD)
b N (non-CJD)
b iLR
c 95% CI
Tau 0-500 5 591 0.06 0.03-0.14
500-1,000 10 138 0.50 0.27-0.92
1,000-3,000 24 65 2.5 1.7-3.9
3,000-10,000 40 27 10.2 6.5-16.0
10,000-∞ 41 5 56.4 22.8-140.0
S100B 0-2.0 8 581 0.09 0.05-0.18
2.0-3.0 19 147 0.85 0.55-1.3
3.0-4.0 26 43 4.0 2.5-6.2
4.0-∞ 69 31 14.6 10.0-21.4
a Interval values are in pg/mL for tau, and in ng/mL for S100B.
b Numbers of patients with test results falling into each interval are shown.
c iLR - interval likelihood ratio. Values are estimates of iLR for CSF tau and
S100B at illustrative cutoff thresholds.
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Figure 3 CSF tau, S100B, and 14-3-3 joint distributions. Scatter plots of CSF concentrations of tau and S100B for (A) 118 sCJD cases and (B)
795 non-CJD cases. Dotted lines mark thresholds of 1,000, 3,000 and 5,000 pg/mL for tau, and 2.5 and 5.0 ng/mL for S100B. Filled and open
circles indicate cases with positive and negative 14-3-3 results, respectively. To maintain S100B scales commensurate between plots, two non-
CJD cases with S100B levels of 43.7 and 46.5 ng/mL and tau levels of 755.4 and 2,182 pg/mL, respectively, were excluded from plot B. Values of
Spearman’s r and respective significance levels are provided for each scatter plot.
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Page 7 of 13interval: 0.27-0.36) than by a positive result for either of
the other two markers (PTP
+ = 0.52, 95% credible inter-
val: 0.45-0.58 for T976;P T P
+ = 0.50, 95% credible inter-
val: 0.43-0.57 for S2.5) (Figure 4).
The importance of taking into account the quantita-
tive level of the assay result is illustrated, for example
with PTP
+ = 0.89 (95% credible interval: 0.79-0.96) for
T10,000 compared with PTP
+ = 0.52 (95% credible inter-
val: 0.45-0.58) for T976 ( F i g u r e4 ) .T h ea d d e dp o w e r
afforded by combining tau and S100B is also evident,
for example by comparing the PTP
+ estimate at the S2.5
+T 976 bivariate threshold (0.73, 95% credible interval:
0.65-0.80) with those at the identical individual thresh-
olds for S100B (0.50, 95% credible interval: 0.43-0.57 at
S2.5) and tau (0.52, 95% credible interval: 0.45-0.58 at
T976). PTP
- values were very low (< 0.1) for all markers
and marker combinations, partly reflecting the relatively
low overall prevalence (pre-test probability) of sCJD in
this study population. However, PTP
- values for some
test results were low enough to indicate that sCJD may
effectively be ruled out by some results; e.g., below the
S2.5 +T a u 976 bivariate threshold, PTP
- = 0.003 (95%
credible interval: 0.000-0.009).
For additional perspective on the influence of pre-test
probability, we noted that the single most common etio-
logically defined subset of diagnoses among non-CJD
patients consisted of non-CJD neurodegenerative dis-
eases, including Alzheimer’s disease (n = 93), Amyo-
trophic Lateral Sclerosis (n = 3), corticobasal
degeneration (n = 5), frontal/frontotemporal dementia
(n = 34), Lewy body disease (n = 25), multiple system
atrophy (n = 7), olivopontocerebellar atrophy (3), Par-
kinson’s disease (n = 7), Pick’s disease (n = 1), primary
progressive aphasia (1), progressive supranuclear palsy
(n = 6), and other neurodegenerative conditions (n = 6).
Restricting attention to this subset of non-CJD patients
and applying logic similar to that described above, pre-
test probability was 0.36 (95% CI: 0.31-0.42), and at an
optimal threshold of T976,L R
+ for tau became 10.0 (95%
CI: 6.5-15.5) with a PTP
+ of 0.85 (95% credible interval:
0.79-0.91).
Discussion
We conducted a large, single-center prospective study of
the performance characteristics of CSF 14-3-3, tau and
S100B in a clinical population with low average pre-test
probability of sCJD (~13%). A number of our findings
are relevant to the needs of the practising clinician who
may need to make diagnostic decisions in a range of
clinical contexts with varying amounts of pre-existing
information, and we discuss some of these implications
below. Methodologically speaking however, we first note
that although sensitivity, specificity, and predictive
values are convenient summary statistics to understand
the accuracies of diagnostic tests, a more general, versa-
tile and practical approach employs likelihood ratios
(LRs) as conversion factors between pre- and post-test
odds, which can easily be converted in turn to diagnos-
tic probabilities [20,21]. LRs offer a number of advan-
tages, as they (i) make use of all of the information in a
2 × 2 table; (ii) are less dependent than predictive values
on disease prevalence; (iii) enable sequential modifica-
tion of diagnostic probabilities for individual patients in
light of accruing information; and (iv) support the more
complete extraction of diagnostic information from
quantitative test data by calculating multi-level (interval)
Table 3 Joint performance characteristics for tau, S100B and 14-3-3
Marker combination Bivariate threshold
a LR
+b ,c 95% CI LR
-b ,d 95% CI
Tau + S100B T976 +S 2.5
c 18.0 12.9-25.0 0.02 0.01-0.09
T3000 +S 2.5 30.3 18.3-50.3 0.06 0.03-0.13
T5000 +S 2.5 35.5 19.2-65.7 0.06 0.03-0.14
T1000 +S 5.0 25.1 13.3-47.5 0.12 0.07-0.20
T3000 +S 5.0 51.2 20.6-127.5 0.30 0.22-0.40
T5000 +S 5.0 57.3 20.7-158.5 0.39 0.31-0.49
Tau + S100B + 14-3-3 T976 +S 2.5
d 18.6 13.1-26.3 0.03 0.01-0.10
T3000 +S 2.5 29.9 18.0-49.6 0.05 0.02-0.13
T5000 +S 2.5 34.9 18.9-64.6 0.05 0.02-0.13
T1000 +S 5.0 29.2 14.5-58.7 0.06 0.03-0.14
T3000 +S 5.0 49.9 20.0-124.3 0.11 0.06-0.20
T5000 +S 5.0 55.6 20.1-154.1 0.11 0.06-0.20
a Bivariate thresholds are defined by combinations of individual thresholds in units of pg/mL (tau) and ng/mL (S100B), as indicated by subscripts.
b LR
+ and LR
- are positive and negative likelihood ratios, respectively. Values are estimates of joint diagnostic likelihood ratios for CSF tau, S100B and 14-3-3
proteins at illustrative bivariate cutoff thresholds.
c To estimate joint LR
+ and LR
- values for tau and S100B, the jointly positive patient subgroup was defined as having both tau and S100B results above the
chosen pair of thresholds, and the jointly negative patient subgroup was defined as having both tau and S100B results below the chosen pair of thresholds.
d To estimate joint LR
+ and LR
- values for tau + S100B + 14-3-3, jointly positive and negative subgroups for tau and S100B were defined as in note c, and
combined with positive and negative 14-3-3 assay results respectively.
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Page 8 of 13LRs [21,28]. They can also serve as convenient generic
indices for performance comparisons among diagnostic
tests, even those with fundamentally different principles
or formats, with LR
+ values in the ranges 1-2, 2-5, 5-10,
and > 10 representing non-useful, low, moderate and
high diagnostic power respectively; for LR
- values the
corresponding ranges are 0.5-1, 0.2-0.5, 0.1-0.2, and <
0.1 [21].
A number of groups have studied CSF 14-3-3, tau and
S100B in sCJD patients and non-CJD controls
[13-15,29-36], and some use has been made of LRs [34].
However, to our knowledge this is the first use of LRs
to estimate and compare the power of these markers to
screen for sCJD in a large, low-prevalence patient popu-
lation. Our estimates indicated clearly that a positive
result for 14-3-3, with its LR
+ estimate of 3.1 (95% CI:
2.8-3.6), offers low diagnostic power versus tau and
S100B with their LR
+ estimates of 7.4 (95% CI: 6.9-7.8)
and 6.6 (95% CI: 6.1-7.1), respectively. This result is
attributable to the lower specificity (0.72) of a positive
14-3-3 test result in our patient population. A similar
estimate of lower specificity (0.74) for 14-3-3 was also
Tau  (pg/mL):
S-100B  (ng/mL):
S-100B  +  Tau:
14-3-3
500
976
3000
5000
10000
1.0
2.5
5.0
2.5  +  976
2.5  +  3000
2.5  +  5000
5.0  +  1000
5.0  +  3000
5.0  +  5000
Pre-test
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Probability  of  sCJD
Post-test
Marker/Threshold
Figure 4 Post-test probabilities for diagnosis of sCJD. Point estimates (closed circles for a positive test result; vertical bars for a negative test
result) and 95% credible intervals (horizontal bars) of post-test probabilities for a diagnosis of sCJD are plotted for various CSF markers and
cutoff thresholds. For each estimate, Bayes’ theorem was applied to CSF marker assay results, and 95% credible intervals were estimated by
modeling on a beta distribution using the software Post_Test_Probabilities. Pre-test probability of sCJD (based on sCJD prevalence in the overall
study population) and 95% confidence interval are indicated by the open circle and the horizontal bar. Cutoff thresholds used are listed on the
left.
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Page 9 of 13reported recently in a clinical population with ~4.5-fold
higher pre-test probability (i.e., prevalence) of sCJD
(~59%) [22]. Noting this, and because our estimates of
sensitivity for tau and S100B (0.91 and 0.87, respec-
tively) were comparable to those of 14-3-3 but specifici-
ties of these two markers (0.88 and 0.87, respectively)
were significantly higher in the same patient population,
we interpret the observed performance disparities to be
more likely due to inherent differences among the mar-
kers than to study-specific patient selection, technical
factors or choice of scoring thresholds.
We also presented quantitative evidence that tau and
S100B each show moderate power to modify diagnostic
probabilities of sCJD at their respective optimal cutoff
thresholds, and high power when the quantitative assay
result is taken into account with the use of interval like-
lihood ratios calculated at different thresholds. Thus, the
extremely high CSF tau concentrations (> 10,000 pg/
mL) observed in 34% (41/120) of the sCJD patients
tested yielded an interval LR of 56.4, which converts a
pre-test sCJD probability of 0.13 to a post-test probabil-
ity of 0.89. Conversely, very low CSF tau concentrations
(< 500 pg/mL) corresponded to an interval LR of 0.06,
which converts the same pre-test probability to a post-
test probability of 0.01. Regarding the choice of thresh-
old value, we found that in our patient population total
diagnostic accuracy as defined by a maximized Youden
Index was robustly optimal at values of 976 pg/mL for
tau, and 2.5 ng/mL for S100B. Both of these values dif-
fer significantly from the widely used consensus thresh-
olds of 1300 pg/mL and 4.2 ng/mL for tau and S100B
respectively using the same ELISA kits. However, selec-
tion of optima that would be generally applicable among
laboratories requires further study.
Strikingly, tau and S100B values jointly above their
respective optimal thresholds yielded a joint LR
+ of 18.0,
significantly higher than achieved by either individual
marker at the same thresholds. This effect may reflect
the combined severity of distinct underlying pathoge-
netic processes in sCJD, as accumulation of CSF tau and
14-3-3 proteins is believed to indicate rapid neuronal
death [18], while S100B is a largely extraneuronal pro-
tein actively secreted from glial cells, suggesting it is pri-
marily a marker of astrogliosis [37]. Point estimates of
LR
- were also lowered by combining tau and S100B,
decreasing from 0.10 and 0.15 for tau and S100B respec-
tively at their individual optimal thresholds to 0.03 at
the corresponding bivariate threshold. Similar effects
were observed in another recent study [22], although
these were not quantified in terms of LRs.
All studies of diagnostic test performance are poten-
tially subject to limitations of design or execution that
can lead to imprecision or bias, and thus to an inability
to interpret or generalize results [38]. We believe that
our large, prospective, sequential, autopsy-based design
reduced many of these potential effects, but two specific
questions merit discussion. One of these concerns accu-
racy of case classification. For example, for 55 of our
127 patients with autopsy-confirmed prion disease,
despite a CJD-like clinicopathological phenotype and no
family history of a similar disease, DNA sequencing
information was not available. Conceivably, some of
these may have been cases of genetic prion disease
rather than sCJD. However, we note that 3 of 77 geneti-
cally analyzed cases with a CJD phenotype proved to
carry a PRNP mutation (E200K in each case); applica-
tion of the resulting estimate of gCJD prevalence in the
study population [3/77 = 0.039 (95% CI: 0.013-0.108)] to
the 55 cases without genetic information yields an
expected number of unrecognized gCJD cases of 2.1
(95% CI: 0.7-5.9), or < 5% (5.9/127) of the sCJD group.
Noting also that diagnostic sensitivity and specificity of
C S F1 4 - 3 - 3 ,t a ua n dS 1 0 0 Bi ng C J Da r es i m i l a rt ot h o s e
seen in sCJD [39], we believe that this residual uncer-
tainty is unlikely to detract significantly from our main
conclusions. Similarly, the low autopsy rate in our non-
sCJD group suggests that some of these 873 cases may
indeed have had prion disease. However, we also expect
this proportion to be small. More specifically, during the
6 calendar years (2004-2009) overlapping the current
study interval for which surveillance data are complete,
the CJDSS reported annual sCJD mortality rates in
Canada of 1.32, 1.30, 1.20, 0.96, 1.21 and 1.36 per mil-
lion, respectively (mean, 1.23), suggesting a low, albeit
undetermined, number of undetected sCJD cases.
A second potential issue has to do with the limited
control that a reference laboratory such as ours has over
pre-analytic factors related to sample collection, storage
and handling that can in principle affect analytic results.
Previous studies have suggested that CSF 14-3-3 and tau
proteins are unusually stable in CSF, yielding highly
comparable results with the same methods we have
employed when samples were subjected to ambient tem-
peratures and/or repeated freeze-thaw cycles [29,40].
Similar methodological studies on the stability of S100B
in CSF appear to be lacking, but our estimates of diag-
nostic sensitivity in our patient population (ca. 90% for
all three of the studied markers) suggests that losses of
sample reactivity caused by suboptimal pre-analytic con-
ditions did not have a large deleterious effect on the
interpretability of our study. With this said however, it
is conceivable that suboptimal pre-analytic sample hand-
ling may have had quantitative effects in some cases,
perhaps explaining some false-negative results or even
lowering the estimated optimum cutoff thresholds.
Future studies should address these questions.
Lastly, if characteristics of a study population do not
adequately reflect those of the patient population to
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mation, it can be difficult to generalize to clinical prac-
tice - an effect sometimes called “spectrum bias” [41], or
simply “spectrum effect” [42]. Because we studied a het-
erogeneous population of patients sharing a broad com-
mon rationale for CSF testing (i.e., suspicion of sCJD),
we suggest that our overall results, which represent a
weighted average of test performance characteristics for
all constituent patient subgroups [42], could prove use-
ful over a broad range of clinical situations. However,
we have provided one illustrative example of how the
clinician, who can sometimes place the suspected sCJD
patient into a particular well-represented subgroup - for
example according to membership in an etiologically
defined disease category (e.g., neurodegenerative disease)
- and thus refine pre-test probability, can further
enhance the diagnostic power of CSF markers. Using
this subgroup criterion with tau protein as the example,
we demonstrated how, using nearly identical test cutoff
thresholds, PTP
+ values rose from 0.52 (95% credible
interval: 0.45-0.58) to 0.85 (95% credible interval: 0.79-
0.91) for patients judged to have neurodegenerative
dementia. Given that clinical examination and diagnostic
investigations commonly undertaken for subacute ence-
phalopathies should often enable the placement of a
particular patient into such a subgroup [8], this type of
illustrative example may prove relevant to clinical prac-
tice by helping to better define the meaning of “appro-
priate clinical context” in relation to use of CSF markers
to diagnose sCJD.
As we found that 14-3-3 performed least well among
the 3 individual markers studied and that the combina-
tion of tau and S100B yielded as much information as
all 3 markers combined, focusing on tau and S100B
among existing CSF markers may be sufficient for most
clinical investigations of sCJD. It may also be appropri-
ate to consider formally incorporating tau and S100B
into enhanced WHO surveillance case definitions for
sCJD [3]. Apart from diagnostic power, another impor-
tant criterion of marker utility is availability of a suitable
technical format. This is particularly relevant for 14-3-3
proteins, which continue to be assayed using immuno-
blot methods [18,43] that are inherently difficult to con-
trol, optimize and standardize in comparison with
ELISA. Although ELISA-format 14-3-3 immunoassays
with demonstrated diagnostic utility have been devel-
oped [32,44-46], these have not yet seen widespread use
or commercial distribution.
Conclusions
In summary, while acknowledging that CSF protein
marker testing in the diagnostic investigation of sCJD
should always be carefully linked to clinical context, our
key finding is that quantitative CSF tau and S100B
assays, particularly in combination, have significant
value even in clinical settings where the pre-test prob-
ability of sCJD is relatively low, and may be an optimal
choice for clinical investigations of sCJD, perhaps with
prioritization of tau. It may also be timely to consider
formally incorporating these markers into sCJD surveil-
l a n c ec a s ed e f i n i t i o n s .T r u eante mortem laboratory
diagnosis of human prion diseases may eventually be
achieved with new approaches based for example on
PrP
Sc [10,11,47], other markers suggested by CJD patho-
biology [48] or discovered by systematic screening [49],
or perhaps a combination of these. In the interim how-
ever, optimized application of known diagnostic markers
will require judicious quantitative assessment of their
performance in realistic clinical settings.
Additional material
Additional file 1: Table S1. Specific non-sCJD diagnoses. The table
lists the names of specific alternate final diagnoses reached for 543
patients initially suspected to have prion disease, and numbers of cases
for each diagnosis.
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